ADC Therapeutics Ltd ADCT 深 沪
已收盘 04-02 16:00:00 美东时间
3.78
-0.020
-0.53%
华盛通- 最 高3.97
- 今 开3.70
- 成交量 135.51万股
- 最 低 3.60
- 昨 收 3.80
- 总市值 4.80亿
- 52周最高 4.98
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 1.13
- 委 比 -73.21%
- 总股本 1.27亿
- 历史最高 56.59
- 量 比 1.77
- 振 幅 9.74%
- 历史最低 0.3599
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ann...
04-02 04:05
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Raises Price Target to $8
HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and raises the price target from $7 to $8.
03-23 18:52
ADC Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
ADC Therapeutics shares are trading higher after the company reported better-th...
03-11 02:07
ADC Therapeutics: Q4 Earnings Insights
ADC Therapeutics (NYSE:ADCT) just disclosed its Q4 earnings on Tuesday, March 1...
03-10 19:32
ADC Therapeutics Q4 Adj. EPS $(0.09) Beats $(0.27) Estimate, Sales $23.058M Beat $21.390M Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.27) by 66.42 percent. This is a 64 percent increase over losses of $(0.25) per share from the
03-10 19:31
Earnings Scheduled For March 10, 2026
Companies Reporting Before The Bell • Ultralife (NASDAQ:ULBI) is likely to repo...
03-10 19:11
ADC Therapeutics Cuts Change-of-Control Fee on ZYNLONTA Deal in New Royalty Agreement, Lowers Potential Payout to $150M Through 2027
ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into an amendment to its royalty purchase agreement with
02-23 20:18
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today ann...
02-23 20:15
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today anno...
02-03 05:05
